TARGET AUDIENCE
This activity is intended for gynecologic oncologists, gynecologists and other healthcare providers involved in the treatment of gynecologic cancers.

OVERVIEW OF ACTIVITY
Gynecologic cancers are comprised of 5 primary cancers affecting the ovaries, uterine corpus (endometrial cancer), uterine cervix (cervical cancer), vulva and vagina. In 2016, it is estimated that approximately 105,890 new cases of gynecologic cancer will be documented in the United States and 30,890 individuals will succumb to these diseases. As with many other tumors, patient outcomes are critically dependent upon effective multidisciplinary care, which in these cases often includes contributions from gynecologic, medical and radiation oncologists as well as pathologists, diagnostic radiologists, oncology nurses and psychosocial services. In addition to the disease- and treatment-related morbidity and mortality associated with gynecologic cancers, pain, fatigue, lymphedema, depression/anxiety, infertility/childbearing and sexual dysfunction are commonly occurring issues that must also be addressed in the care of these patients. Interestingly, despite many commonalities, each of these diseases is in fact quite distinct and consequently management algorithms employed for each are varied.

These video proceedings from a CME symposium held during the Society of Gynecologic Oncology’s 2016 Annual Meeting on Women’s Cancer feature discussions with leading researchers with an expertise in gynecologic oncology regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist gynecologic oncologists and other healthcare providers with the formulation of up-to-date clinical management strategies for various gynecologic cancers.

LEARNING OBJECTIVES
• Evaluate current standard therapies and emerging treatment options, and use this information to appropriately select and sequence therapeutic approaches for patients with primary and recurrent ovarian cancer (OC).
• Recognize the mechanisms of action, emerging efficacy data and toxicity profiles of investigational agents in OC to effectively prioritize clinical trial opportunities for appropriate patients.
• Describe the rationale for targeting angiogenic pathways in gynecologic cancer, and consider the role of the anti-VEGF antibody bevacizumab in the initial and long-term treatment of advanced OC, cervical cancer and endometrial cancer.
• Implement a long-term clinical plan for the management of metastatic cervical cancer and endometrial cancer, incorporating existing, recently approved and investigational treatments.
• Compare and contrast the mechanisms of action, efficacy and safety/toxicity of investigational immunotherapies for the treatment of ovarian, cervical and endometrial cancers, and counsel appropriately selected patients about the availability of ongoing clinical trials.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GynOnc16/EmergingStrategies/CME.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Michael Birrer, MD, PhD**
Professor, Medicine
Harvard Medical School
Director, Gillette Center for Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts

**Advisory Committee:** Acceleron Pharma, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc, Merrimack Pharmaceuticals Inc, OXiGENE Inc, Roche Laboratories Inc, Sanofi, Threshold Pharmaceuticals Inc.

**Thomas J Herzog, MD**
Paul and Carolyn Flory Professor
Deputy Director, UC Cancer Institute
Vice Chair, Quality and Safety
Department of Obstetrics and Gynecology
University of Cincinnati
Cincinnati, Ohio

**Advisory Committee:** Amgen Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Pfizer Inc, Roche Laboratories Inc.

**Bradley J Monk, MD**
Professor and Director
Division of Gynecologic Oncology
Vice Chair, Department of Obstetrics and Gynecology
University of Arizona Cancer Center — Phoenix
Creighton University School of Medicine at Dignity Health
St Joseph’s Hospital and Medical Center
Phoenix, Arizona

**Consulting Agreements:** Advaxis Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Cervical Pharma Inc, Clovis Oncology, Genentech BioOncology, Gradalis Inc, ImmunoGen Inc, INSYS Therapeutics Inc, Merck, NuCana Biomed, Pfizer Inc, OXiGENE Inc, Roche Laboratories Inc, TESARO Inc, Vermillon Inc;

**Contracted Research:** Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Janssen Biotech Inc, Lilly, Morphotek Inc, TESARO Inc; **Speakers Bureau:** AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Janssen Biotech Inc, Lilly, Morphotek Inc, TESARO Inc;

**Advisory Committee:** Amgen Inc, Array BioPharma Inc, Genentech BioOncology, Janssen Biotech Inc, Lilly, Morphotek Inc, TESARO Inc;


**CONSULTING GYNECOLOGIC ONCOLOGISTS** — The following consulting gynecologic oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

**Ioannis Alagkiozidis, MD**
Chief of Gynecologic Oncology
Bronx Lebanon Hospital
Bronx, New York

No relevant conflicts of interest to disclose.

**Barbara Buttin, MD**
Practice Leader, Gynecologic Oncology
Northwestern Medicine Regional Medical Group
Winfield, Illinois

No relevant conflicts of interest to disclose.

**Joanie Mayer Hope, MD**
Medical Director, Providence Infusion Center
Managing Partner, Alaska Women’s Cancer Care
Director of Gynecologic Oncology
Native Alaska Medical Center
Anchorage, Alaska

No relevant conflicts of interest to disclose.
Lynn D Kowalski, MD  
Nevada Surgery and Cancer Care  
Medical Director, Las Vegas Institute for Robotic Surgery  
Vice Chief of Staff, Mountainview Hospital  
Las Vegas, Nevada  

Consulting Agreement: IntegraGen; Speakers Bureau: AstraZeneca Pharmaceuticals LP.

Lyndsay J Willmott, MD  
Assistant Professor  
Division of Gynecologic Oncology  
Creighton University School of Medicine at Dignity Health  
St Joseph’s Hospital and Medical Center  
Phoenix, Arizona  

No relevant conflicts of interest to disclose.


Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Genentech BioOncology and ImmunoGen Inc.

Hardware/Software Requirements:  
A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more  
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later  
Adobe Flash Player 10.2 plug-in or later  
Adobe Acrobat Reader  
(Optional) Sound card and speakers for audio

Last review date: July 2016  
Expiration date: July 2017
Thomas J Herzog, MD


Pignata S et al. A randomized multicenter phase III study comparing weekly versus every 3 weeks carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicenter Italian Trials in Ovarian Cancer (MITO-7) — European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10) and Gynecologic Cancer Intergroup (GCIG) trial. Proc ASCO 2013;Abstract LBA5501.


Angeles Alvarez Secord, MD, MHSs

Aghajanian C et al. A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. Proc ASCO 2015;Abstract 5500.


Lorusso D et al. Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: The MITO END-2 trial. Proc ASCO 2015;Abstract 5502.


Michael Birrer, MD, PhD

Borghaei H et al. Phase 1 study of IMGN853, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) in patients (Pts) with epithelial ovarian cancer (EOC) and other FRA-positive solid tumors. Proc ASCO 2015;Abstract 5558.


Bradley J Monk, MD


Disis ML et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial. *Proc ASCO* 2015;Abstract 5509.


